These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Efavirenz's complications.
    Journal: GMHC Treat Issues; 1998 May; 12(5):6. PubMed ID: 11365477.
    Abstract:
    DuPont Merck cautions that efavirenz cuts saquinavir levels in the blood by 60 percent over the course of the day. An exception is the protease inhibitor combination saquinavir/ritonavir, wherein ritonavir appears to reverse efavirenz's effect on saquinavir. No data is available on taking all three drugs. The company intends to present information on the drug interactions at the World AIDS Conference in Geneva. UpJohn is considering selling its HIV drugs or at least finding a partner for further drug development. Delavirdine, the company's FDA-approved NNRTI, has suffered due to the lack of trial data demonstrating a solid anti-HIV effect and due to an inconvenient dosing schedule. The company is now working on an NNRTI designed to work against delavirdine-resistant HIV. While UpJohn is decreasing its presence in HIV drug development, Glaxo is increasing its anti-HIV product line. Glaxo has two new antiretrovirals that will soon reach the market and has also recently bought a family of structurally-related NNRTIs from Hoechst Marion Roussel.
    [Abstract] [Full Text] [Related] [New Search]